Tag: FIGO 2023
-
Can IVIM MRI Outperform ADC in Predicting Aggressive Endometrial Carcinoma Subtypes under FIGO 2023
Introduction and clinical context Endometrial carcinoma (EC) is the second most common gynecologic cancer worldwide, with rising incidence and a spectrum of histological subtypes. The 2023 FIGO revision reshapes staging by emphasizing prognostic risk and tumor biology rather than purely anatomical spread. In this setting, magnetic resonance imaging (MRI) remains pivotal for preoperative evaluation. Beyond…
-
IVIM MRI May Outperform ADC in Predicting Aggressive Endometrial Carcinoma Subtypes Under FIGO 2023
Introduction Endometrial carcinoma (EC) remains a leading gynecologic cancer globally, with incidence and mortality trending upward in some regions. The 2023 FIGO update shifted the focus from purely anatomical staging to prognostic risk and tumor biology. In this context, functional MRI techniques—especially intravoxel incoherent motion (IVIM) diffusion imaging—are gaining attention as non-invasive biomarkers for preoperative…
-
Can IVIM MRI outpace ADC in predicting aggressive endometrial carcinoma subtypes under FIGO 2023 guidance? New imaging insights
Introduction: IVIM MRI and the FIGO 2023 framework Endometrial carcinoma (EC) remains a leading gynecologic cancer worldwide, with rising incidence and diverse histological subtypes. The FIGO 2023 classification emphasizes prognosis based on biological behavior, separating tumors into aggressive and non-aggressive groups. Magnetic resonance imaging (MRI) has long been the backbone of preoperative assessment, balancing anatomical…